A combination drug or a fixed-dose combination ( FDC ) is a medicine that includes two or more active ingredients combined in a single dosage form . Terms like "combination drug" or "combination drug product" can be common shorthand for an FDC product (since most combination drug products are currently FDCs), although the latter is more precise if in fact referring to a mass-produced product having a predetermined combination of drugs and respective dosages (as opposed to customized polypharmacy via compounding ). And it should also be distinguished from the term "combination product" in medical contexts, which without further specification can refer to products that combine different types of medical products—such as device/drug combinations as opposed to drug/drug combinations. When a combination drug product (whether fixed-dose or not) is a "pill" (i.e., a tablet or capsule), then it may also be a kind of " polypill " or combopill.
3-608: Hydrochlorothiazide/triamterene , also known as co-triamterzide , is a fixed-dose combination medication of hydrochlorothiazide and triamterene . It is used to treat high blood pressure and edema (swelling). Specifically it is used in those who develop low blood potassium (hypokalemia) when on only hydrochlorothiazide. It is taken by mouth . Side effects may include nausea, trouble sleeping, dizziness, feeling light headed with standing , kidney problems, allergies , and muscle cramps. Other serious side effects may include high blood potassium . Use in pregnancy and breastfeeding
6-413: A single disease (such as with antiretroviral FDCs used against AIDS ). However, FDCs may also target multiple diseases/conditions. In cases of FDCs targeting multiple conditions, such conditions might often be related—in order to increase the number of prospective patients who might be likely to use a given FDC product. This is because each FDC product is mass-produced, and thus typically requires having
9-590: Is not generally recommended. Use in those with significant kidney problems is not recommended. It decreases blood pressure mainly by hydrochlorothiazide while triamterene decreases the amount of potassium lost. The combination was approved for medical use in the United States in 1965. In 2022, it was the 116th most commonly prescribed medication in the United States, with more than 5 million prescriptions. Fixed-dose combination Initially, fixed-dose combination drug products were developed to target
#10989